Initial English translation and validation of a symptom-specific quality of life (QOL) module for acute myeloid leukemia (AML)

Abstract

8183 Background: QOL is becoming increasingly important in oncology and is usually measured using general cancer scales and symptom-specific scales. AML is an aggressive hematological tumor that affects primarily older adults and often responds poorly to standard treatment. Understanding QOL will assist in treatment decision-making, symptom palliation, and evaluation of new biologic agents. Yet there is no validated English-language symptom module for use in AML. Methods: In this pilot study, we set out to translate and perform English-language validation of an existing German symptom-specific module for AML designed by Schumacher and Kuchler for use with the European Organization for the Research and Treatment of Cancer (EORTC) QLQ-C30 (Leukemia 1998; 12:586). Forward-backward translation of the 20-item module (7 subscales) was performed. Face and content validation of the English module were assessed by a panel of hematologists and QOL researchers. The module was then administered along with the QLQ-C30 to 14 English-speaking patients aged 60 or older with newly diagnosed AML at baseline and at 1 and 4 months. Semi-structured interviews were conducted with patients to assess clarity and comprehensiveness. Results: 10 men and 4 women with a mean age of 73 years completed the instruments on up to 3 occasions. Completion rates were 100%. The module was completed in a mean of 5 minutes (range 3–8). Item analysis indicated adequate scaling for all items. One question required minor rewording. No additional items were suggested by patients for inclusion. There were moderate correlations between global QOL on the QLQ-C30 and both general symptoms and diagnosis-specific symptoms in the symptom module. Pain subscales in the symptom module correlated well with the QLQ-C30 pain subscale. Conclusion: Administration of a symptom-specific QOL module is feasible in older patients with AML. The module has face and content validity, preliminary construct validity, and can be administered in a short time frame. Further testing is required to examine reliability, construct validity, and responsiveness. No significant financial relationships to disclose.